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Abstract: We aimed to assess the survival benefits of primary tumor resection (PTR) followed
by chemotherapy in patients with asymptomatic stage IV colorectal cancer with asymptomatic,
synchronous, unresectable metastases compared to those of upfront chemotherapy alone. This was
an open-label, prospective, randomized controlled trial (ClnicalTrials.gov Identifier: NCT01978249).
From May 2013 to April 2016, 48 patients (PTR, n = 26; upfront chemotherapy, n = 22) diagnosed with
asymptomatic colorectal cancer with unresectable metastases in 12 tertiary hospitals were randomized
(1:1). The primary endpoint was two-year overall survival. The secondary endpoints were primary
tumor-related complications, PTR-related complications, and rate of conversion to resectable status.
The two-year cancer-specific survival was significantly higher in the PTR group than in the upfront
chemotherapy group (72.3% vs. 47.1%; p = 0.049). However, the two-year overall survival rate was
not significantly different between the PTR and upfront chemotherapy groups (69.5% vs. 44.8%, p =
0.058). The primary tumor-related complication rate was 22.7%. The PTR-related complication rate
was 19.2%, with a major complication rate of 3.8%. The rates of conversion to resectable status were
15.3% and 18.2% in the PTR and upfront chemotherapy groups. While PTR followed by chemotherapy
Cancers 2020, 12, 2306; doi:10.3390/cancers12082306 www.mdpi.com/journal/cancers
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resulted in better two-year cancer-specific survival than upfront chemotherapy, the improvement in
the two-year overall survival was not significant.
Keywords: primary tumor resection; colorectal neoplasm; synchronous unresectable metastasis;
non-curative resection; neoplasm metastasis; chemotherapy; overall survival
1. Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related death according to the global cancer statistics [1]. Patients with stage IV CRC who
are diagnosed with distant metastasis at initial CRC diagnosis make up 20% of the total cases of
CRC [2]. In the treatment of stage IV CRC, primary tumor resection (PTR) has been performed
to relieve tumor-related complications and to avoid life-threatening conditions such as intractable
bleeding, intestinal obstruction, and perforation. However, it is still controversial whether upfront
PTR is necessary in patients with asymptomatic, synchronous, unresectable metastatic CRC.
PTR in patients with asymptomatic stage IV CRC can prevent impending obstruction and emergent
situations caused by the primary cancer. Since these complications are associated with increased
mortality and morbidity, upfront PTR is preferred to avoid tumor-related complications, which can
develop during chemotherapy. In addition, a decrease in tumor burden after PTR is expected to increase
the potential survival. Several retrospective studies and meta-analyses have reported survival benefits
of PTR compared with upfront chemotherapy [3–5]. According to the analysis of the Surveillance,
Epidemiology, and End Results (SEER) database by Tarantino et al. [6,7], PTR results in prolonged
overall and cancer-specific survival compared to upfront chemotherapy. In addition, a nationwide
study in the Netherlands found that PTR followed by systemic chemotherapy showed survival benefits
compared with chemotherapy alone [8].
In contrast, upfront chemotherapy is also widely used for asymptomatic stage IV CRC as an
initial treatment. The advance of modern systemic chemotherapy using combined chemotherapy
with molecular target agents increased the survival rate of patients with metastatic CRC dramatically,
from six months to nearly 24 months [9–13]. The time-trend analysis of patients with stage IV CRC
in the United States demonstrates that survival has increased in spite of a decreased rate of PTR in
the modern era [14]. In addition, delayed initial chemotherapy and potential risks of postoperative
complications are regarded as drawbacks of PTR as the initial treatment in patients with asymptomatic
metastatic CRC.
The survival benefits of PTR in patients with asymptomatic metastatic CRC remain controversial.
The oncologic effects of PTR are difficult to validate due to a lack of results from randomized controlled
trials and limitations of retrospective data from a heterogeneous patient selection. Therefore, this
study aimed to evaluate whether PTR followed by chemotherapy, improves survival and decreases
complication rates compared with upfront chemotherapy in patients with asymptomatic, synchronous,
unresectable metastatic CRC in a multicenter randomized controlled trial.
2. Results
The study period was conducted from May 2013 to April 2016. It ended early due to a lack
of patient enrollment and cessation of funding. Patients were recruited from October 2013 to May
2015. The final data collection was on 30 April 2016. The median follow-up period was 15.0 months
(interquartile range (IQR), 8.5–21.5 months). A total of 52 patients from 12 hospitals in Korea were
randomized and allocated into two groups: the upfront chemotherapy only group (Arm 1, n = 25)
and the PTR with chemotherapy group (Arm 2, n = 27), as shown in Figure 1. According to the
intention-to-treat protocol, 22 patients from Arm 1 and 26 patients from Arm 2 were evaluated. Four
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patients who did not receive treatment were excluded. Four more patients were lost to follow-up,
resulting in a final count of 21 patients in Arm 1 and 23 patients in Arm 2.
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Figure 1. CONSORT flow diagram. ITT, Intention-to-treat.
2.1. Baseline Patient haracteristics
There were no statistical differences in age, sex, body ass index, erican Society of
Anesthesiologists (ASA) score, perfor ance status, or co- orbidities bet een the PTR group and the
upfront chemotherapy group. The sigmoid colon was the most frequent primary cancer site in both
groups. Liver metastasis occurred in 50.0% of patients in the upfront chemotherapy group and 61.5%
of patients in the PTR group. Synchronous multiple metastases were present in 45.5% of the upfront
chemotherapy group and in 23.1% of the PTR group, but this difference was not statistically significant
(p = 0.320). A single metastasis was present in 54.5% of the upfront chemotherapy group and in 76.9%
of the PTR group. The initial carcinoembryonic antigen level was not significantly different between
the groups (Table 1).
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Age, year: 58.8 ± 12.1 (32–74) 62.3 ± 11.8 (40–81) 0.318 †
Sex:
Male 12 (54.5) 21 (80.8) 0.051 ‡
Female 10 (45.5) 5 (19.2) -
BMI, kg/m2: 23.1 ± 2.7 (18.4–28.3) 22.9 ± 3.9 (13.6–34.4) 0.846 †
ASA score: 1.000 ‡‡
1 9 (40.9) 12 (46.2) -
2 10 (45.5) 11 (42.3) -
3 1 (4.5) 1 (3.8) -
unknown 2 (9.1) 2 (7.7) -
ECOG performance status: 0.714 ‡‡
0 13 (59.1) 18 (69.2) -
1 7 (31.8) 7 (26.9) -
2 2 (9.1) 1 (3.8) -
Co-morbidity, n (%): 0.710 ‡‡
Cardiovascular disease 7 (31.8) 9 (34.6) -
Pulmonary disease 0 (0.0) 2 (7.7) -
Metabolic disease 2 (9.1) 3 (11.5) -
None 13 (59.1) 12 (46.2) -
Location of the primary cancer: 0.706 ‡‡
Ascending colon 6 (27.3) 4 (15.4) -
Transverse colon 1 (4.5) 2 (7.7) -
Descending colon 0 (0.0) 1 (3.8) -
Sigmoid colon 11 (50.0) 10 (38.5) -
Rectosigmoid junction 1 (4.5) 2 (7.7) -
Rectum 3 (13.6) 7 (26.9) -
Synchronous metastasis: 0.320 ‡‡
Liver only 11 (50.0) 16 (61.5) -
Lung only 1 (4.5) 2 (7.7) -
Paraaortic lymph node only 0 (0.0) 2 (7.7) -




1 12 (54.5) 20 (76.9) -
2 10 (45.5) 5 (19.2) -
≥3 0 (0.0) 1 (3.8) -
Initial CEA: 121.8 (16.6–1316.1) * 47.6 (26.6–510.6) * 0.649 ††
PTR, primary tumor resection; BMI, body mass index; ASA, American Society of Anesthesiologists; ECOG, Eastern
Cooperative Oncology Group; CEA, carcinoembryonic antigen. Continuous variables are described as mean
± standard deviation (range); *, median (interquartile range, IQR); categorical variables are described as n (%);
† student t-test; †† Mann–Whitney U test; ‡ Chi-Square test; ‡‡ Fisher’s exact test.
2.2. Clinical Manifestations of Upfront Chemotherapy Group (Arm 1)
The conversion rate of initially unresectable metastatic tumors to resectable tumors was 18.2%
in the upfront chemotherapy group, as shown in Table 2. Liver metastases were reduced in size,
rendering them resectable in four patients (18.2%) during palliative first-line chemotherapy using
FOLFIRI with target agents (two patients with cetuximab and two patients with bevacizumab). Four
patients (18.2%) underwent operations during chemotherapy. Two patients underwent palliative PTR,
and two patients underwent surgery to treat intestinal obstruction. In the upfront chemotherapy group,
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five patients (22.7%) required interventional therapies—three gastrointestinal stent insertions (13.6%),
and two salvage radiotherapies (9.1%).
Table 2. Clinical manifestations in the upfront chemotherapy group.
Upfront Chemotherapy Group (Arm 1)
n = 22
Resectable conversion, n (%): 4 (18.2)
Liver: 4 (18.2)
Details for the operations of Arm 1: 8 (36.4)
Resectable conversion *: 4 (18.2)
LAR with liver resection 2 (9.1)
AR with liver resection 1 (4.5)
Rt. hemicolectomy with liver resection 1 (4.5)
Palliative PTR **: 2 (9.1)
LAR 1 (4.5)
AR 1 (4.5)
Operations due to intestinal obstruction: 2 (9.1)
Rt. hemicolectomy 1 (4.5)
Laparoscopic AR 1 (4.5)
Intervention: 5 (22.7)
GI stent insertion 3 (13.6)
Salvage radiotherapy 2 (9.1)
LAR, low anterior resection; AR, anterior resection; Rt., right; PTR, primary tumor resection; GI, gastrointestinal;
* operation due to conversion to resectable status; ** operation for palliative primary tumor resection.
2.3. Clinical Manifestations of the PTR Group (Arm 2)
PTR was performed to resect the primary tumor completely before chemotherapy. Anterior
resections and low anterior resections were each performed in eight (30.8%) patients. Sixteen open
surgeries (61.5%) were performed, compared to 10 laparoscopic surgeries (38.5%). Three patients
(11.5%) underwent synchronous operations during PTR. The mean length of hospital stay after the
PTR operation was 11.8 ± 6.7 days (range, 6–34 days). Three patients were re-admitted within 30 days
post-operation due to septic shock, general weakness, or postoperative ileus. One patient (3.8%) died
within 30 days postoperatively due to pneumonia with sepsis. The initial adjuvant chemotherapy after
PTR was started within 24.8 ± 11.4 days of PTR. The pathology reports showed that 65.4% of patients
had T3 tumors, and that 88.5% of the primary tumors were moderately differentiated. The mean tumor
size was 6.0 cm, and the mean number of positive regional lymph nodes was 5.0. Nineteen patients
(73.1%) had a lymphovascular invasion. The conversion rate of initially unresectable metastatic tumors
to resectable tumors was 15.3% in the PTR group (Table 3).
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Table 3. Clinical and pathologic manifestations in the PTR group.
PTR Group (Arm 2)
n = 26
Operative outcomes for PTR
PTR procedures:
Right hemicolectomy 5 (19.2)
Left hemicolectomy 1 (3.8)
Anterior resection 8 (30.8)
Low anterior resection 8 (30.8)
Intersphincteric resection with CAA 2 (7.7)
Subtotal colectomy 1 (3.8)




Stoma formation: 2 (7.7)
Synchronous operations:
Segmental resection of small bowel 1 (3.8)
Salpingo-oophorectomy 1 (3.8)
Liver resection, not curative 1 (3.8)
Postoperative clinical outcomes
Hospital stay, day: 11.8 ± 6.7 (6–34)
Re-admission *: 3 (11.5)
Septic shock 1 (3.8)
General weakness 1 (3.8)
Postoperative ileus 1 (3.8)
Mortality * 1 (3.8)
Time to beginning adjuvant chemotherapy, day 24.8 ± 11.4 (13–66)




T4a/T4b 8 (30.8)/1 (3.8)
Histologic grade of the primary tumor:
Well-differentiated 1 (3.8)
Moderately differentiated 23 (88.5)
Poorly differentiated 2 (7.7)
Tumor size, cm: 6.0 ± 1.8 (3.4–10.0)
Number of harvested lymph nodes: 26.2 ± 11.1 (8–52)
Number of positive lymph nodes: 5.0 ± 5.0 (0–18)
Lymphovascular invasion: 19 (73.1)
Resectable conversion: 4 (15.3)
Liver 3 (11.5)
Lung 1 (3.8)
PTR, primary tumor resection; CAA, coloanal anastomosis; *, evaluated within 30 days post-operation.
2.4. Regimens for Chemotherapy
The most common first-line chemotherapy used in both groups was the FOLFIRI regimen (73.1%
of the PTR group patients and 90.9% of the upfront chemotherapy group patients). Anti-Vascular
endothelial growth factor(VEGF) therapeutics were used more frequently in the upfront chemotherapy
group than in the PTR group. FOLFOX chemotherapy was the most used second-line regimen for
palliative chemotherapy (53.8% of the PTR group patients and 45.5% of the upfront chemotherapy
group patients). Various regimens were used as third-line chemotherapies (Table S1).
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2.5. Complications Between PTR and Upfront Chemotherapy Groups
In the upfront chemotherapy group, the primary tumor-related complication rate was 22.7%.
Three patients (13.6%) experienced grade IIIa intestinal obstructions, and two patients (9.1%) had grade
IIIb intestinal obstructions. Six patients (27.3%) experienced grade I chemotherapy-related toxicities.
Postoperative complications developed in five patients (19.2%) after PTR. Only one major postoperative
complication (3.8%) occurred, as one patient had a grade V complication due to pneumonia with sepsis
after PTR. The rate of PTR-related grade I–II complications was 15.4%. There was no anastomotic
leakage after PTR in this study. Chemotherapy-related toxicities accounted for 26.9% of grade I
complications in the PTR group. One patient had a grade IV complication caused by pneumonia
during chemotherapy (Table 4).
Table 4. Comparison of complications between the PTR and upfront chemotherapy groups.
Grade
Upfront Chemotherapy Group (Arm 1)
n = 22





































Grade IV - - - 1 (3.8%)Pneumonia
Grade V - - 1 (3.8%)Pneumonia with sepsis -
PTR, Primary tumor resection; HFS, Hand-foot syndrome.
2.6. Survival Outcomes
The two-year overall survival rate of the PTR group was not significantly higher than that of the
upfront chemotherapy group, despite a drastic difference (69.5% in the PTR group and 44.8% in the
upfront chemotherapy group, p = 0.058). However, the two-year cancer-specific survival rate of the
PTR group was significantly higher than that of the upfront chemotherapy group (72.3% in the PTR
group and 47.1% in the upfront chemotherapy group, p = 0.049) (Figure 2).
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3. Discussion
In this trial, PTR followed by systemic chemotherapy showed improved two-year cancer-specific
survival in patients with asymptomatic CRC with synchronous unresectable metastases compared with
upfront chemotherapy alone. However, the two-year overall survival rate after PTR plus chemotherapy
was not statistically significant compared with upfront chemotherapy. Although major postoperative
complications occurred in 3.8% of patients after PTR, 22.7% of patients experienced major tumor-related
complications during upfront chemotherapy.
The goal of PTR in patients with asymptomatic stage IV CRC is to prevent primary tumor-related
complications. Although the tumors are asymptomatic at diagnosis, life-threatening tumor-related
complications, including massive tumor bleeding, bowel obstruction, or perforation, can occur as
the disease progresses. In addition, chemotherapy-related myelosuppression decreases the potential
recovery, increasing the mortality in these emergent situations. In contrast, there are reports that
the rates of emergent interventions are relatively low in patients using combination chemotherapy
(11–14%) [15,16]. In a retrospective study by Poultsides et al. [15] involving patients with synchronous
stage IV CRC receiving triple-drug chemotherapy with or without bevacizumab as the initial treatment,
7% of patients required emergent operations due to primary cancer obstruction or perforation and 4% of
patients required therapeutic interventions. McCahill et al. [16] reported that the 24-month cumulative
rate of major morbidities in patients undergoing chemotherapy with mFOLFOX6 plus bevacizumab
without PTR was 16.3%. In our study, 22.7% of patients developed primary tumor obstruction during
upfront chemotherapy. Three of these patients (13.6%) were treated with colonic stent insertion, and
two patients (9.1%) underwent emergent surgery. The primary tumor-related complications observed
in this study are comparable to those previously reported in retrospective studies and are all major
morbidities at or above grade III complications. In contrast, major complications occurred in 3.8% of
patients after PTR in this study.
In the clinical setting, it is difficult to predict the necessity of therapeutic interventions during
chemotherapy in patients with asymptomatic metastatic CRC. The asymptomatic tumor of each patient
differs in size, depth of invasion, and rate of circumferential narrowing of the bowel lumen. These
differences make the decision to perform PTR prior to chemotherapy challenging. Regular endoscopic
surveillance and categorization of asymptomatic tumors into subgroups based on the risks of primary
tumor-related complications are useful tools to determine whether PTR should be performed in patients
with asymptomatic stage IV CRC.
In this trial, the two-year cancer-specific survival rate after PTR followed by chemotherapy was
higher than that of chemotherapy alone. There were concerns that delaying systemic chemotherapy
for PTR would negatively affect survival due to the slow recovery and potential postoperative
complications. However, the time interval to begin chemotherapy after PTR was 24.8 postoperative
days, and the mean hospital stay was 11.8 days, which is comparable with major colorectal resection
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procedures [17,18]. Although one patient had difficulties beginning chemotherapy due to major
complications of pneumonia with sepsis after PTR, most patients received chemotherapy without
difficulty. Most of the PTR-related complications were limited to grade I–II complications. Some
retrospective analyses have suggested that patients who undergo PTR have better initial performance
status, which may confound the results of the two-year survival rates [19]. However, our trial was
randomized, and the results showed that the two-year cancer-specific survival of the PTR group
was better than that of the upfront chemotherapy group. Fast recovery with fewer postoperative
complications and the prevention of potential tumor-related complications during chemotherapy are
some advantages of PTR that may play a role in improving cancer-specific survival.
In contrast, it is unclear whether PTR has benefits for overall survival. Many retrospective
and meta-analyses reported the survival benefits of PTR, followed by chemotherapy compared with
chemotherapy alone [4,20,21]. However, in our trial, the PTR group did not have a statistically significant
survival benefit compared to the upfront chemotherapy group, despite a much higher survival rate.
The difference observed in our study is comparable with the result of the first interim analysis of
the JCOG1007 study, which is a randomized phase III trial comparing PTR plus chemotherapy and
chemotherapy alone [22,23]. The median overall survival of the trial was 25.9 months in patients who
underwent PTR plus chemotherapy and 26.7 months in patients who underwent chemotherapy alone
(p = 0.69) [23]. Patient survival rates have improved with the development of new chemotherapeutic
agents. The 17.4-month overall survival observed in patients receiving FOLFIRI monotherapy increased
to 25.0 months in patients receiving combined chemotherapies with bevacizumab and to 28.7 months
in patients receiving cetuximab, as reported in the FIRE-3 trial [24,25]. The National Cohort Study
of the US population from 1988 to 2010 showed that the overall survival of stage IV CRC improved
despite a decreasing rate of PTR [14]. Thus, it was believed that fewer surgeries are required to
improve survival. However, after a propensity score matching analysis of this database to remove
confounding factors, the rates of the overall and cancer-specific survival increased simultaneously
in patients who underwent PTR and in patients who received upfront chemotherapy [6]. The
development of novel chemotherapeutic agents increased the overall survival in patients who received
PTR followed by chemotherapy as well as in patients who received chemotherapy alone. The rates
of conversion to resectable metastases were comparable between the groups of this study—18.2% in
the upfront chemotherapy group and 15.3% in the PTR group. Despite the hypothesis that surgical
stress and inflammatory conditions after PTR may negatively impact survival, a good response to
chemotherapeutics was observed in both groups regardless of PTR. Although current clinical guidelines
do not recommend palliative PTR, the overall survival benefit of PTR followed by chemotherapy
should be investigated comprehensively with consideration for treatment response and potential risks
from primary tumor progression.
Although this study tried to evaluate the role of PTR in the treatment of unresectable metastatic
CRC, there are several inevitable limitations. First, the early termination of the study resulted in a
lack of data and short follow-up periods, which led to low statistical power. Difficulties in the study
enrolment process and the abrupt cessation of research funding were obstacles to the completion of
this study. In particular, performing the operations and reaching the final goal successfully are more
difficult in clinical trials involving a surgical intervention than in those involving a medical intervention.
Active participation regarding undergoing surgical interventions such as PTR was challenging for
the patients as well as the surgeons. In addition, continued research funding and support while
awaiting the final results are required to conclude the study. Second, we did not assess the quality of
life, which is an important factor for selecting treatment methods for stage IV CRC. Third, the rate of
left-sided colon cancer was higher than right-sided colon cancer in both groups. In addition, patients
who had peritoneal metastases, which leads to bowel obstruction more frequently than metastasis
to other sites, were excluded. Fourth, although most patients in this study were treated with the
recommended chemotherapeutic regimens, some patients were unable to receive this treatment. Lastly,
we did not perform genetic analyses to identify patients with incurable stage IV CRC who might
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benefit from PTR. Nevertheless, the results of this study are crucial, as we evaluated the oncologic
impact of PTR in a homogeneous study population in which confounding factors were decreased due
to randomization. A low rate of postoperative complications and the potential to prevent possible
complications of primary tumors without delaying chemotherapy make PTR a beneficial treatment
option in patients with stage IV CRC. Randomized controlled trials for PTR in patients with incurable
stage IV CRC—SYNCHRONOUS (ISRCTN trial registry: 30964555) and CAIRO4 (ClinicalTrials.gov
Identifier: NCT01606098)—are ongoing [22,26,27]. It is expected that the role of PTR will be well
defined when the comprehensive results of these trials are reported in the near future.
4. Materials and Methods
4.1. Study Design
This was an open-label, prospective, randomized controlled trial that took place in 12 tertiary
hospitals in Korea. All patients were screened, then randomized in a 1:1 ratio into one of the two
arms—Arm 1 (upfront chemotherapy alone) and Arm 2 (chemotherapy after PTR). Patients allocated
into Arm 1 received chemotherapy without PTR within two weeks after randomization. Patients of
Arm 2 received PTR within two weeks after randomization and then began to receive chemotherapy
within two months after PTR. PTR was defined as the complete resection of the primary tumor (R0
resection) with negative resection margins and lymphadenectomy. The regimen of chemotherapy
was determined by following the guidelines of the National Health Insurance Service of Korea. The
expected accrual period was three years, and the follow-up period was two years in the initial study
protocol. This study was performed following the Declaration of Helsinki and Good Clinical Practice
guidelines, with each participating institution obtaining approval from their own institutional review
board (No.3-2014-0127). The detailed study protocol was published and registered (ClinicalTrials.gov
Identifier: NCT01978249) [28].
4.2. Participants
Patients older than 20 years who were diagnosed with resectable colon or upper rectal cancer
with unresectable metastatic lesions without primary tumor-related symptoms, including intestinal
obstruction, intractable bleeding, and perforation were evaluated. Among them, patients with an
Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 and an ASA score of less than
three were enrolled after providing informed consent. Patients who had mid or low rectal cancer with
an anal verge measuring less than 10 cm, unresectable primary cancer, or peritoneal carcinomatosis
were excluded from the study. Patients who underwent an incomplete PTR (R2 resection) were also
excluded. Unresectable metastases were defined as metastases to two adjacent segments of the liver
that could not be preserved after liver resection, a remnant liver volume of <30% of the total liver
volume, more than five metastatic lung lesions, requiring a resection larger than a lobectomy, lung
metastases resulting in insufficient respiratory function, even if the number of lesions was less than
five, or metastases to the brain, bone, neck, mediastinum, or retroperitoneal area. [28].
4.3. Sample Size Calculation and Randomization
This study hypothesized that the two-year overall survival rate of Arm 2 would improve by 10%
compared to Arm 1 (31% vs. 21%). According to the inequality design, a two-sided log-rank test
was performed with an α-error of 0.05 and a power of 80%. The drop-out rate was expected to be
10%. PASS version 12 (NCSS statistical software, Kaysville, UT, USA) was used for the sample size
calculation of 240 patients for each group. The patients were allocated into each group according to a
1:1 ratio of randomization, which was stratified by age (<70 vs. ≥70), ECOG performance status (0 vs.
1–2), ASA score (1–2 vs. 3), and target agent (use or no use).
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4.4. Study Endpoints and Outcome Parameters
The primary endpoint of this study was the comparison of the two-year overall survival rates
between the PTR group and the upfront chemotherapy group. The patients were followed up every
three months after the initiation of chemotherapy.
The secondary endpoints measured primary tumor-related complication rates, PTR-related
complication rates, and rate of conversion to resectable status after chemotherapy. All adverse
events after PTR were graded using the Clavien–Dindo classification for surgical complications [29].
Chemotherapy-related toxicities were evaluated based on the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0 [30]. PTR-related complications were evaluated in
patients of Arm 2, and tumor-related complications were estimated in patients of Arm 1. Neutropenia
during chemotherapy was not reported as chemotherapy-related toxicity because it was observed in
most patients who received chemotherapy. The rate of conversion of initially unresectable metastatic
tumors to surgically resectable tumors during the study period was estimated in both groups.
4.5. Data Collection and Monitoring
All clinical data were recorded and collected in the eVelos System, which is a web-based clinical
research management system provided by the National Cancer Center, Korea. The final data were
confirmed by a principal investigator. The entire process, including data collection, records, and
reporting of adverse events, was monitored by a committee that was certificated at each center. The
interim results were reported annually to the Ministry of Health and Welfare of Korea.
4.6. Statistical Analysis
Statistical analyses were performed using the SPSS 23 (SPSS INC., Chicago, IL, USA) and SAS 9.3
(SAS Institute Inc., Cary, NC, USA) software programs. Categorical variables were compared using the
chi-square test or Fisher’s exact test. Continuous variables were analyzed using the Student’s t-test or
Mann–Whitney U test. The two-year overall survival was estimated using Kaplan-Meier methods. p
values less than 0.05 were considered as statistically significant.
5. Conclusions
PTR followed by chemotherapy improved the two-year cancer-specific survival of patients with
asymptomatic stage IV CRC compared with chemotherapy alone. PTR-related major complications
were few compared to primary tumor-related complications that developed during chemotherapy. The
marginal significance of a p value of 0.058 may indicate a possible survival benefit of PTR, although our
data did not show an obvious statistical difference in the two-year overall survival. The comprehensive
analyses from the results of ongoing randomized controlled trials may provide an answer for the role of
PTR followed by chemotherapy in patients with asymptomatic synchronous incurable metastatic CRC.
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